Reviewing Icon Plc (ICLR) & Eiger BioPharmaceuticals (EIGR)
Icon Plc (NASDAQ: ICLR) and Eiger BioPharmaceuticals (NASDAQ:EIGR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.
This table compares Icon Plc and Eiger BioPharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Icon Plc has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Eiger BioPharmaceuticals has a beta of 2.55, suggesting that its stock price is 155% more volatile than the S&P 500.
Institutional & Insider Ownership
91.5% of Icon Plc shares are owned by institutional investors. Comparatively, 59.9% of Eiger BioPharmaceuticals shares are owned by institutional investors. 44.0% of Icon Plc shares are owned by company insiders. Comparatively, 28.8% of Eiger BioPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Icon Plc and Eiger BioPharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Icon Plc||$1.72 billion||3.61||$393.57 million||$4.94||23.25|
|Eiger BioPharmaceuticals||N/A||N/A||-$46.28 million||($5.69)||-2.43|
Icon Plc has higher revenue and earnings than Eiger BioPharmaceuticals. Eiger BioPharmaceuticals is trading at a lower price-to-earnings ratio than Icon Plc, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for Icon Plc and Eiger BioPharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Icon Plc presently has a consensus price target of $116.00, indicating a potential upside of 1.00%. Eiger BioPharmaceuticals has a consensus price target of $32.60, indicating a potential upside of 135.38%. Given Eiger BioPharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Eiger BioPharmaceuticals is more favorable than Icon Plc.
Icon Plc beats Eiger BioPharmaceuticals on 10 of the 13 factors compared between the two stocks.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company’s information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient’s blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.